Los Angeles, CA. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer within the commercial Unmanned Aerial Vehicle (“UAV”), Remotely Piloted Aircraft Systems (“RPAS”), and Unmanned Vehicle Systems (“UVS”) sectors, is pleased to announce that it will be the exclusive supplier using its patented drone technologies to deliver Varigard’s pathogen and virus surface sanitizer to arenas, stadiums and concert venues.
Varigard™ is a patented bio-based organic sanitizer and is the only product that has been lab tested to sequester and kill COVID-19, STAPH, MRSA, E Coli, A. BAUMANNII (EBOLA,SARS and others) and PNEUMONIA for a minimum of 2+ hours. Varigard™ comes in a hand sanitizer gel, surface disinfectant or atomized version for spraying large venues. All 3 products carry the 2+ hour sequestration and kill efficacy.
“We are excited to team up with Draganfly and allow large venues to start serving their customers with a COVID-19 lab proven sanitizer that not only lasts for 2+ hours, but contains no toxic chemicals.” said Mike Paolillo, Varigard’s managing partner. “It is critical that we deliver cost effective and safe products to help get our world back to normal. Our partnership with Draganfly will allow us to do just that!”.
"The surface disinfecting market size is surging and expected to reach $1.5 billion by 2027, due in part to the requirement to disinfect large areas like stadiums. Varigard™ has already established a technical leadership position and we look forward to providing the most advanced drones and services to their customers,” said Cameron Chell, CEO of Draganfly.
Varigard™, LLC is an Alabama based company focused on delivering safe and effective solutions using their patented organic polymers to reimagine products in the world today. They have several ground-breaking technologies that were formulated to sequester and kill dangerous pathogens for extended periods of time before they can enter the human body. Varigard™ is growing quickly in the US market while they are working on expansion into other countries in 2021.
For more information on Varigard™, please visit us at www.varigard.com.
Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.
For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.
This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements include, but are not limited to, statements with respect the successful integration of the Varigard‘s products onto drones, market size of the surface disinfecting market and the efficacy of Varigard products. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
© 2020 GlobeNewswire, Inc. All Rights Reserved.